A world-class organisation needs a world-class website
3 December 2014
Today we launch the website we’ve dreamed about!
We built this new site to be a foundation for our communication to the world. And we designed it with you in mind. We’ve rewritten the content and redesigned the structure so you can get informed and stay informed quickly and easily on whatever device you happen to be using.
Here’s a few things we’re excited to show you:
- New design that looks great on your phone, tablet or desktop and is easier to navigate.
- Melanoma glossary to define melanoma jargon.
- Treatment pages that will leave you informed but not keep you up reading all night.
- Sophisticated search function to make finding things easy.
- Blogs for patients, melanoma community news and research developments.
- Easier giving with automatic online donation receipting.
- Integration with our Facebook page and Twitter feed.
- And that’s just the beginning!
We thought our new site deserved a bright new logo too. So we designed one that remembers who we are while bringing a bright freshness that we think reflects the hope and excitement we have for the future. Is that the sun rising in the middle of our umbrella, dawning a bright new day for the future of melanoma research and care? Maybe so…
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.